ANTHELMINTIC AND ANTICOCCIDAL 3-CARBAMOYL-4-HYDROXYCOUMARINS, METHOD OF USE AND COMPOSITIONS

Abstract: This invention relates to compounds of formula (I), which are useful for killing and controlling worms (Helminths).

Description: ANTHELMINTIC AND ANTICOCCIDIAL 3-CARBAMOYL-4-HYDROXYCOUMARINS. METHOD OF USE AND COMPOSITIONS SUMMARY OF THE INVENTION This invention pertains to a new method for killing and controlling worms (Helminths;. and new formulations for killing and controlling worms in animals, and new chemical compounds. The invention is more particularly directed to a new method for killing and controlling parasitic worms in animals with novel 3-carbamoyl-4-hydroxycoumarins, and to new anthelmintic formulations comprising the same. In addition, various 3-carbamoyl-4-hydroxycoumarins demonstrate anticoccidial activity. The anthelmintic 3-carbamoyl-4-hydroxycoumarins have the general structural Formula I. The anticoccidial 3-carbamoyl-4-hydroxycoumarins have the general structural Formula IW. BACKGROUND OF THE INVENTION The diseases or groups of diseases described generally as helminthiasis are due to infection of the animal with parasitic worms known as helminths. Helminthiasis and helminthosis are prevalent and may lead to serious economic problems in valuable domestic warm-blooded animals such as sheep, swine, cattle, goats, dogs, cats, horses, poultry and man. Among the helminths, the groups of worms known as nematodes, trematodes and cestodes cause widespread and often¬ times serious infections in various species of animals including man. The most common genera of nematodes. trematodes and cestodes infecting the animals referred to above are Dictyocaulus. Haemonchus. Trichostrongylus. Ostertapia. Nematodirus. Cooperia. Bunostomum. Oesopha g pstomum. Chabertia, Strongyloides. Trichuris. Fasciola. Dicrocoelium. Enterobius. Ascaris. Toxascaris. Toxocara. Ascaridia. Capillaria. Heterakis. Ancylostoma. Uncinaria. Dirofilaria. Onchocerca. Taenia. Moniezia. Dipylidium. Metastrongylus. Triodontophorus. Macracanthorhynchus. Hyostrongylus. and Strongylus. Some of these genera attack primarily the intestinal tract while others inhabit the stomach, lungs, liver and subcutaneous tissues. The parasitic infections causing helminthiasis and helminthosis lead to anemia, malnutrition, weakness, weight loss, unthriftiness, severe damage to the gastrointestinal tract wall and, if left to run their course, may result in death of the infected animals. The anthelmintic activity of various 3-carbamoyl- -hydroxycoumarins has been disclosed. However, their action is not always satisfactory, especially when low concentrations are applied. U.S. Patent 3,991,204 discloses various 3-carbamoyl-4-hydroxycoumarins, including 3\4'-dichlorcH4^iydroxy-2-oxo-2H-l-benzopyran-3-carboxaniIide, 3'-chloiϋ-4-hydroxy-2-oxo-2H-l- benzopyran-3-carboxanilide, 3'-fluoro-4-hydroxy-2-oxo-2H-l-benzopyran-3-carboxanilide, 4'- fluor^4 ιydroxy-2-oxo-2H-l-benzopyran-3-carboxanilide and 2\4'-difiuoro-4^ιydroxy-2-oxo-2H-l- benzopyran-3-carboxanilide, for controlling helminths. DE 2643476 and 2643428 disclose various 3-carbamoyl-4-hydroxycoumarins, including 3-N-(4-bromophenyl)-carbamoyl-4-hydroxycoumarin, 3-N-(4-chlorophenyl)-carbamoyl-4- hydroxycoumarin, and 3-N-(4-fluorophenyl)-carbamoyl-4-hydroxycoumarin as pesticides. EP 14372 discloses quatenary aluminum salts of 4-hydroxy-3-(4-trifluoromethylphenyl)-coumarin. DE 3012642 Al discloses various 3-carbamoyl-4-hydroxycoumarins, including 3-N-(4- trifluoromethoxy)-carbamoyl-4-hydroxycoumarin and 3-N-(4-chloro-difluoromethoxy)- carbamoyl-4-hydroxycoumarin, as pesticides. U.S. Patent 4,766,144 discloses various 3-carbamoyl-4-hydroxycoumarins. including 3-N- (4-trifluoromethoxyphenyl )-carbamoyl-4-hydroxycoumarin, 3-N-(3-chloro-4- trifluoromethoxyphenyl)-carbamoyl-4-hydroxycoumarin, 3-N-(3-trifluoromethyl-4- methoxyphenyl)-carbamoyl-4-hydroxycoumarin and 3-N-(3-chloro-4-trifluorothiophenyl)-carbamoyl- 4-hydroxycoumarin, for controlling helminths. U.S. Patent 4,078.075 discloses 3-N-(4-trifluoromethylphenyl)-carbamoyl-4- hydroxycoumarin as useful for combating insect pests. U.S. Patent 3,511,856 discloses 3-(alkoxyphenylcarbamoyl)-4-hydroxycoumarins useful as bactericides and pesticides. 3-N-(3-chlorophenyl)-8-methyl-carbamoyl-4-hydroxycoumarin and other 3-carbamoyl-4- hydroxycoumarins are disclosed in Pharmazie, 39(2), 86-91 (1984). 3-N-(2-naphthyl)-6-phenyl-carbamoyl-4-hydroxycoumarin, 3-N-(2-naphthyl)-carbamoyl- 4-hydroxycoumarin and other 3-carbamoyl-4-hydroxycoumarins are disclosed in Chem. Chron. 1 (3.4), 199-202 (1972). 3-N-(2-hydroxyphenyl)-carbamoyl-4-hydroxycoumarin, 3-N-(4-hydroxyphenyl)-6-halo- carbamoyl-4-hydroxycoumarin and other 3-carbamoyl-4-hydroxycoumarins are disclosed in Chem. Ther. 2(6), 430-440 (1967). Japanese Patent 4667 (February 25, 1967) describes the preparation of various 3- carbamoyl-4,7-dihydroxycoumarins, including 3-(5-methyl-l,3,4-thiadiazol-2-yl-carbamoyl)-4,7- dihydroxycoumarin, 3-(l,3-thiazole-2-yl-carbaraoyl)-4,7-dihydroxycoumarin, 3-(4- chloroanilinocarbamoyl)-4,7-dihydroxycoumarin and 3-(3-trifluoromethylanilinocarbamoyl)-4,7- dihydroxycoumarin. Japanese Patent 4668 (February 25, 1967) describes the preparation of various 3- carbamoyl-4-hydroxy-7-nitrocoumaτins and 3-carbamoyl-4-hydroxy-7-acetamidecoumarins, including 3-(5-methyl-l,3,4-thiadiazol-2-yl-carbamoyl)-4-hydroxy-7-nitrocoumarin and 3-(4- trifluoromethylanilinocarbamoyl)-4-hydroxy-7-acetamidecoumarin. French Patent 1,216,966 discloses various 3-(substituted)-carbamoyl-4-hydroxycoumarins, including 3-φyridin-3-yl)-carbamoyl-4-hydroxycoumarins and 3-φyridin-2-yl)-carbamoyl-4- hydroxycoumarins having bactericidal and antifungicidal. See also CA 55:17556f, CA 60:507g, and U.S. Patent 3,122,577. U.S. Patent 3,293,255 discloses 3-(alkyl-substituted)-carbamoyl-4-hydroxycoumaτins. CA 72(19): 100433y discloses 4-hydroxy-6-phenyl-3-(phenylcarbamoyl)-coumarin. CA 78(13):84191j discloses 4-hydroxy-N-l-naphthyl-2-oxo-6-phenyl-2H-l-benzopyran-3-carbox- amide. DETAILED DESCRIPTION OF THE INVENTION The 3-carbamoyl-4-hydroxycoumarins of the invention are represented by Formula I wherein X is selected from the group consisting of (1) 4-halophenyl (A); (2) 4-R 4 phenyl (A') (3) (5-R' 5 )-l,3,4-thiadiazol-2-yl (B); (4) (2-SR" 5 )-l,3,4-thiadiazol-5-yl (C); (5) pyridin-2-yl (X) (6) pyridin-3-yl (Y) (7) pyridin-4-yl (Z) (8) pyrimidin-5-yl (F); (9) pyrazin-2-yl (G); (10) pyrimidin-2-yl (H); (11) -NH-phenyl (I); (12) 4-fdi(Cι-C 5 )alkoxyphosphonomethyl]phenyl (J); or (13) 4-(pyridin-4-ylmethyl)phenyl (K); wherein the variable substituents (1) and (2) are optionally substituted at the 2 position of the phenyl moiety with halogen (Ci, Br, F, or I, preferably F); wherein the variable substituents (5)-(ll) are optionally substituted with one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C j -C5 alkyl or C!-C5 alkoxy; wherein the variable substituent (13) is optionally substituted in the pyridinyl moiety with one or two members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C j - C 5 alkyl or C1-C5 alkoxy; wherein R is selected from the group consisting of hydrogen, phenyl, halogen (Cl, Br, F or I), CN, CF 3 , CJ-C5 alkyl or C j -Cs alkoxy, with the proviso that when X is 4-halophenyl (A), R is Cl, F, Br, CF 3 or phenyl; wherein R 4 is selected from cyano (-C«N), trifluoromethyl, ^^4 alkyl (preferably t- butyl), phenylhydroxymethyl (-CHOH-phenyl), hexafluoro-2-hydroxyisopropyl (-C(CF 3 ) 2 OH), or trifluoromethoxy (-O-CF3). wherein R' 5 is selected from a halogen (Cl, Br, F, or I) atom, cyano, -CF 3 , -CF 2 C1, -CF 2 CF 3 , benzyl, benzyl substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br. F or I), CN, CF 3 , C j -C5 alkyl or C j -C5 alkoxy], pyridin-2- yl, pyridin-2-yl substituted with [one. two or three members selected from the group consisting of halogen (Cl. Br, F or I), CN, CF 3 , C r C 5 alkyl or C r C 5 alkoxy]. pyridin-3-yl, pyridin-3-yl substituted with [one, two or three members selected from the group consisting of halogen (Cl. Br, F or I). CN, CF 3 . C j -C 5 alkyl or Cι~C 5 alkoxy], pyridin-4-yl, pyridin-4-yl substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I). CN. CF 3 , C r C 5 alkyl or C r C 5 alkoxy]; wherein R" 5 is selected from hydrogen, C j -C 5 alkyl, halogen (Cl, Br, F, or I), cyano, - CF 3 , -CF 2 C1. -CF 2 CF 3 , phenyl, phenyl substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C j -C 5 alkyl or C!-C 5 alkoxy], benzyl, benzyl substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C r C 5 alkyl or C r C 5 alkoxy], pyridin-2-yl, pyridin-2-yl substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C 1 -C 5 alkyl or C r C 5 alkoxy], pyridin-3-yl, pyridin-3-yl substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C1-C5 alkyl or C C 5 alkoxy], pyridin-4-yl, pyridin-4-yl substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C1-C5 alkyl or C j -C 5 alkoxy]; pyridin-2-yl(CH 2 )-, pyridin-2-yl(CH 2 )- substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , Cι-C 5 alkyl or C_-C 5 alkoxy], pyridin-3-yl(CH 2 )-, pyridin-3-yl(CH 2 )- substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br. F or I). CN. CF 3 , C 1 -C5 alkyl or C j -C 5 alkoxy]. pyridin-4-yl(CH 2 )-, pyridin-4-yl(CH 2 )- substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C j ^ alkyl or C- j -C ζ alkoxy]; or hydrates or a pharmaceutically acceptable salt thereof; other than: 3-[N-[4-tτifluoromethylphenyl)carbamoyl]-4-hydroxycoumarin, 3-[N-[4-trifluoromethoxyphenyl)carbamoyl]-4-hydroxycoumarin 3-[N-(5-benzyl- 1 ,3 ,4-&iadiazol-2-yl)carbamoyI]-7-cMoro-4-hydroxy∞umarin, 7-chloro-4-hydroxy-3-[N-[5-(2-pyridinylmethyl)thio-l ,3,4-thiadiazol-5- yl]carbamoyl]coumarin, 7-chloro-4 ιydroxy-3-[N-(5-phenyl-l,3,4-thiadiazol-2-yl]carbamoyl]coumarin, 3-[N-(2-(benzylthio-l,3,4-thiadiazol-5-yl)carbamoyl]-7-chloro-4-hydroxycoumarin, 3-[N-(3,6-dichloropyridazin-4-yl)carbamoyl]-4-hydroxycoumarin, 4-hydroxy-3-[N-(2-pyridinylcarbamoyl)courmarin, 4-hydroxy-3-[N(3-pyridinylcarbamoyl)courmarin, 7-trifluoromethyl-3-[N-(3-chloro-5-trifluoromethylpyridin-2-yl)carbamoyl]-4- hydroxycoumarin. 3-[N-(6-chloropyridin-3-yl)carbamoyl]-4-hydroxycoumarin, 3-[N-(6-methylpyridin-2-yl)carbamoyl]-4-hydroxycoumarin, 3-[N-(5-bromopyridin-2-yl)carbamoyl]-7-methoxy-4-hydroxycoumarin, or 3-[N-(2,6-dichloropyridin-4-yl)carbamoyl]-4-hydroxycoumarin. Halogen refers to a bro o, chloro, iodo or fluoro atom. Halo refers to a chloro, bromo or fluoro atom. 4-Halophenyl (Formula A) refers to 4-chorophenyl, 4-fluorophenyl and 4-bromophenyl, preferably 4-bromophenyl. R is preferably selected from the group consisting of halo (Cl. Br, or F) or CF 3 . Examples of 4-[di(C 1 -C5)alkoxyphosphonomethyl]phenyl include 4-(diethoxy- phosphonomethyl)phenyl, 4-(dimethoxyphosphonomethyl)phenyl and 4-(ethoxymethoxy- phosphonomethy phenyl . Examples of C ] -C 5 alkyl are methyl, ethyl, propyl, butyl, pentyl and isomeric forms thereof. Examples of CJ-C5 alkoxy are methoxy, ethoxy, propoxy, butoxy, pentoxy and isomeric forms thereof. Pharmaceutically acceptable refers to those properties and/or substances which are acceptable to the patient from a pharmacologically-toxicological point of view and to the manufacturing pharmaceutical chemist from a physical-chemical point of view regarding composition, formulation, stability, patient acceptance and bioavailability. C - C means the carbon content of various hydrocarbon-containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety. Thus (C j -C 3 ) alkyl refers to alkyl of one to 3 carbon atoms, inclusive or methyl, ethyl, propyl, and isopropyl. Preferred 3-carbamoyl-4-hydroxycoumarins of Formula I are where X is 4-halophenyl, i.e. a 3-N-(4-halophenyl)-carbamoyl-4-hydroxycoumarin (Formula IA) or l,3,4-thiadiazol-2-yl, i.e. a 3-N-(l ,3,4-thiadiazol-2-yl)-carbamoyl-4-hydroxycoumarin (FormulalB) substitutedatthe5-position with a halogen (Cl, Br, F, or I) atom, cyano (-CN), -CF 3 , -CF 2 C1, -CF 2 CF 3 , -CN, C^ alkyl, benzyl optionally substituted with [one member selected from the group consisting of halogen, -CN or trifluoromethyl], or pyridinyl optionally substituted with [one member selected from the group consisting of halogen, -CN or trifluoromethyl]. More preferred 3-carbamoyl^-hydroxycoumarins of Formula I are where X is 1,3,4- thiadiazol-2-yl, i.e. a 3-N-(l,3,4-thiadiazol-2-yl)-carbamoyl-4-hydroxycoumarin (Formula IB) substituted at the 5-position with a halogen (Cl, Br, F, or I) atom, cyano, -CF 3 , -CF 2 C1 or -CF 2 CF 3 . Particularly preferred anthelmintic 3-carbamoyl-4-hydroxycoumarins of Formula I are: 7-chloro-4-hydroxy-3-[N-[5-(trifluoromethyl)-l,3,4-thiadiazol-2-yl]carbamoyl]coumarin (Cpd. #1 1). 7-chloro-4-hydroxy-3-[N-[5-(chlorodifluoromethyl)-l ,3,4-thiadiazol-2- yl]carbamoyl]coumarin (Cpd. #17), 7-chloro-4-hydroxy-3-[N-[5-(trifluoromethyl-difluoromethyl)- l,3,4-thiadiazol-2-yl]carbamoyl]eoumarin (Cpd. #18), 3-[N-(4-chlorophenyl)carbamoyl]-7-fluoro- 4-hydroxycoumarin (Cpd. #6), 3-[N-(4-fluorophenyl)carbamoyl]-7-trifluoromethyl-4- hydroxycoumarin (Cpd. #8). Particularly preferred anticoccidial 3-carbamoyl-4-hydroxycoumarins of Formula IW are: 3-[N-2,4-difluorophenyl)carbamoyl]-7-bromo-4-hydroxycoumarin (Cpd. #53) and 3[N-(4- chlorophenyl)carbamoyl]-7-bromo-4-hydroxycoumarin (Cpd. #54). A is 4-halophenyl (preferably 4-bromophenyl) optionally subsituted at the 2 position with halogen (Cl, Br, F or I, preferably F). B is l,3,4-thiadiazol-2-yl substituted at the 5-position with halogen (Cl, Br, F, or I), cyano, -CF 3 , -CF 2 C1, -CF 2 CF 3 , benzyl, benzyl substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 . C j ^ alkyl or C j ^ alkoxy], pyridin-2-yl, pyridin-2-yl substituted with [one, two or three members selected from the group consisting of halogen (Cl. Br, F or I), CN, CF 3 , C j -C 5 alkyl or C j -C5 alkoxy], pyridin-3- yl, pyridin-3-yl substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C r C 5 alkyl or C r C 5 alkoxy], pyridin-4-yl, pyridin-4-yl substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br. F or I), CN, CF 3 , C r C 5 alkyl or C r C 5 alkoxy]. C is 5-(SR" 5 )-l,3,4-thiadiazol-2-yl wherein R" 5 is selected from hydrogen, halogen (Cl, Br, F, or I), cyano, -CF 3 , -CF C1, -CF 2 CF 3 , phenyl, phenyl substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C j ^ alkyl or C1-C5 alkoxy], benzyl, benzyl substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C j ^ alkyl or C j ^ alkoxy], pyridin-2- yl, pyridin-2-yl substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C^ alkyl or C^ alkoxy], pyridin-3-yl, pyridin-3-yl substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C j -Cs alkyl or C r C 5 alkoxy], pyridin-4-yl, pyridin-4-yl substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C!-C 5 alkyl or C^ alkoxy]. F is pyrimidin-5-yl optionally substituted with one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C1-C5 alkyl or C1-C5 alkoxy. G is pyrazin-2-yl optionally substituted with one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C C 5 alkyl or C C 5 alkoxy. H is pyrimidin-2-yl optionally substituted with one. two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C j -C 5 alkyl or C j -C 5 alkoxy. I is -NH-phenyl optionally substituted with one, two or three members selected from the group consisting of halogen (Cl, Br, F or I). CN, CF 3 , C j -C 5 alkyl or C r C 5 alkoxy. J is 4-[di(C j -C 5 )alkoxyphosphonomethyl]phenyl. K is 4-(pyridin-4-ylmethyl)phenyl wherein the pyridinyl moiety is optionally substituted with C r C 5 alkyl. X is pyridin-2-yl optionally substituted with one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C j -C 5 alkyl or C j -C 5 alkoxy. Y is pyridin-2-yl optionally substituted with one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C j -Cs alkyl or C -C ζ alkoxy. Z is pyridin-2-yl optionally substituted with one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C1-C5 alkyl or C j -C 5 alkoxy. The 3-carbamoyl-4-hydroxycoumarins of the invention (Formula I) are readily prepared by refluxing the appropriate 4-hydroxycoumarin esters (1) with the appropriate arylamines (2) (CHART A, Scheme A) or by reacting the appropriate 4-hydroxycoumarins (4) with the appropriate arylisocyanates (5) (CHART A, Scheme B). The reaction of Scheme A is carried out in a nitrogen atmosphere and refluxed in the presence of a suitable solvent or solvent mixture in order to completely dissolve the starting materials; for example, xylene, xylene/DMF, DMSO or DMF. After the reaction is complete, the mixture is cooled to room temperature to precipitate the desired product. The precipitate is filtered and washed with a suitable solvent(s) such as methanol, xylene, ether, ethyl acetate or chloroform to give the product in s yield of about 30-90%. The product can be recrystallized from DMF, DMSO or preferably dioxane. The acylation reaction of Scheme B is carried out in the presence of a suitable base such as a tertiary amine, for example, N-methylmorpholine, DBU (l,8-diazabicyclo[5.4.0]undec-7-ene), DBN (l,5-diazabicyclo[4.3.0]non-5-ene), DABCO (l,4-diazabicyclo[2.2.2]octane), pyridine, or triethylamine. Preferably, the coumarin esters (1) are obtained from the corresponding salicylates as outlined in CHART B. Acetylation of the salicylic acid 6 followed by treatment of the resultant acetate 7 with refluxing thionyl chloride provides the acid chloride 8. Addition of the acid chloride 8 to a solution of sodium methoxide and diethyl malonate in toluene, followed by heating at reflux provides the desired coumarin ester 1. Improved yields are obtained by the addition of the acid chloride 8 to the malonate anion (1.2 eq) generated with sodium hydride, followed by cyclization of the resultant acylated malonate 9 with sodium methoxide in refluxing tetrahydrofuran (THF). The starting amines (2) and isocyanates (5) are commercially available or prepared by knownmethods. The following detailed examples/procedures describe how to prepare various 3-carbamoyl- 4-hydroxycoumarins of the invention and are to be construed as merely illustrative, and not limitations of the preceding disclosure in any way whatsoever. Those skilled in the art will promptly recognize appropriate variations from the procedures both as to reactants as well as to reaction conditions and techniques. Example 1: Preparation of 3-[N-(4-bromophenyl)carbamoyl]-7-chloro-4-hydroxy- coumarin, Compound No. 1. A mixture of 3-ethoxycarbonyl-4-hydroxy-7-chlorocoumarin (8.0 g) and 4-bromoaniline (5.1 g) is heated to reflux in xylene (60 ml) and dimethyl formamide ( 5 ml) for one hour. Upon cooling, the desired product crystallizes. The crude product is filtered, washed with diethyl ether, and dried to give 10.4 gm. of the title compound having a melting point of 228.4° C. Following the general procedure of Example 1, except using the appropriate coumarin esters (1) and amines (2) and making non-critical variations, the following compounds are prepared. Melting Example No./ Point Compound No. Chemical Name °C 3-[N-(4-bromophenyl)carbamoyl]-7-trifluoromethyl-4- 234 hydroxycoumarin 3-[N-(4-bromophenyl)carbamoyl]-7-fluoro-4- 212.5 hydroxycoumarin 3-[N-(4-chlorophenyl)carbamoyl]-7-chloro-4- 213.5 nydroxycoumarin 3-[N-(4-chlorophenyl)carbamoyl]-7-trifluoromethyl-4- 219.9 hydroxycoumarin 3-[N-(4-chlorophenyl)carbamoyl]-7-fluoro-4- 212.2 hydroxycoumarin 3-[N-(4-fluorophenyl)carbamoyl]-7-chloro-4- 212.8 hydroxycoumarin 3-[N-(4-fluorophenyl)carbamoyl]-7-trifluoromethyl-4- 194.1 hydroxycoumarin 3-[N-(4-fluorophenyl)carbamoyl]-7-fluoro-4- 235.6 hydroxycoumarin Example 10: Preparation of 3-[N-(4-bromophenyl)carbamoyl]-7-fluoro-4- hydroxycoumarin, triethylamine salt. A mixture of 7-fluoro-4-hydroxycoumarin (180 mg), p-bromophenyl isocyanate (198 mg), and triethylamine (101 mg) is heated to reflux in tetrahydrofuran (THF, 6 ml) for one hour. After the reaction is complete, the solvent is evaporated and the resulting solid is triturated with methanol to give 200 mg of the title compound having a melting point of 187-189° C. Example 11: Preparation of 7-chloro-4-hydroxy-3-[N-[5-(trifluoromethyl)-l,3,4- thiadiazol-2-yl]caτbamoyl]coumarin. Compound No. 11. A mixture of 3-ethoxycarbonyl-4-hydroxy-7-chlorocoumarin (6.0 gm) and 2-amino-5- trifluromethyl-l,3,4-thiadiazole (3.7 gm) is heated to reflux in xylene (170 ml) for one hour. After 70 ml of the xylene has distilled off over about 2 hours, the resulting mixture is heated to reflux in xylene for 17 hours. Upon cooling, the desired product crystallizes. The solid is washed with 20 ml of acetonitrile and dried in vacuo to give 8 gm of the title compound having a melting point of 246° C. Following the general procedure of Example 11, except using the appropriate coumarin esters and amines and making non-critical variations, the following compounds are prepared. Melting Example NoJ Point Compound No. Chemical Name °C 12 4-hydroxy-3-[N-[5-(trifluoromethyl)-l,3,4-thiadiazol-2- 249.3 y 1 ] carbamoy 1 ] coumarin 13 4-hydroxy-7-methyl-3-[N-5-(trifluoromethyl)- 1 ,3,4- 273.9 thiadiazol-2-yl]carbamoyl]coumarin 14 4-hydroxy-7-methoxy-3-[N-[5-(trifluoromethyl)- 1,3,4- 258- thiadiazol-2-yl]carbamoyl]coumarin 259.5 15 7-fluoro-4-hydroxy-3-[N-[5-(trifluoromethyl)-l,3,4- 240.5 thiadiazol-2-yl]carbamoyl]coumarin 16 7-trifluoromethyl-4-hydroxy-3-[N-[5-(trifluoromethyI)- 264 1 ,3,4-thiadiazol-2-yl]carbamoyl]coumarin (dec) 17 7- ιloro-4-hydroxy-3-[N-[5-(chlorodifluoromethyl)-l,3,4- 234-238 thiadiazol-2-yl]carbamoyl]coumarin 18 7-chloro-4-hydroxy-3-[N-[5-(trifluoromethyl-difluoro- 214-218 methyl)-l,3,4-thiadiazol-2-yl]carbamoyl]coumarin 19 4-hydroxy-3-[N-[5-(trifluoromethyldifluoromethyl)-l,3,4- 225-227 thiadiazol-2-yl]carbamoyl]coumarin 20 7-fluoro-4-hydroxy-3-[N-[5-(trifluoromethyl-difluoro- 205-207 methyl)- 1 ,3 ,4-thiadiazol-2-yl] carbamoyljcoumarin 21 4-hydroxy-3-[N-(5-phenyl-l ,3,4-thiadiazol-2-yl)- 227.2 carbamoyljcoumarin 22 3-[N-(6-chloropyridazin-3-yl)carbamoyl]-4-hydroxy- 253.6 coumarin 23 3-[N-(5-benzyl-l,3,4-thiadiazol-2-yl)carbamoyl]-4- 241.7 hydroxycoumarin 24 3-[N-(5-benzyl-l,3,4-thiadiazol-2-yl)carbamoyl]-4- 275.1 hydroxy-7-methylcoumarin (dec) 25 3-[N-[5-(4-chlorophenyl)methyl-l,3,4-thiadiazol-2- 226.5- yl]carbamoyl]-4-hydroxycoumarin 230.5 26 7-chloro-3-[N-[5-(4-chlorophenyl)methyl-l,3,4-thiadiazol- 221-223 2-yl]carbamoyl]-4-hydroxycόumarin 27 3-[N-[2-[(4-fluorophenyl)methyI]thio-l,3,4-thiadiazol-5- 224.0- yl]carbamoyl]-4-hydroxycoumarin 226.5 (dec) 28 4-hydroxy-3-[N-(2-mercapto-l,3,4-thiadiazol-5-yl)- 304-306 carbamoyljcoumarin (dec) 29 4-hydroxy-3-[N-[2-(methylthio)-l,3,4-thiadiazol-5-yl]- 239.3 carbamoyljcoumarin 30 4-hydroxy-3-[N-[5-(3,5-dichloropyridin-2-yl)thio-l,3,4- 233-239 thiadiazol-2-yl]carbamoyl]coumarin 31 4-hydroxy-3-[N-[2-(2-pyπdinylmethyl)thio-l,3,4-thia- 217.4 diazol-5-yl]carbamoyl]coumarin 32 4-hydroxy-7-methyl-3-[N-[2-(2-pyridinylmethyl)thio-l,3,4- 237-239 thiadiazol-5-yl]carbamoyl]coumarin (dec) 33 3-N-[2-(4-pyridinylmethyl)thio-l,3,4-thiadiazol-5-yl]- 226- carbamoyl-4-hydroxycoumarin 228.5 34 3-[N-[2-(benzylthio)-l,3,4-thiadiazol-5-yl]carbamoyl]-4- 215.1 hydroxycoumarin 35 3-[N-(5-bromopyrimidin-2-yl)carbamoyl]4-hydroxy- 266.5 coumarin 36 4-hydroxy-3-[N-(phenylamino)carbamoyl]coumarin 215.6 37 4-hydroxy-3-[N-[(4-bromophenyl)amino]carbamoyl]- 237.2 coumarin 38 4-hydroxy-3-[N-(2-bromo-l,3,4-thiadiazol-5-yl)- 252.5 carbamoyljcoumarin (dec) 39 4-hydroxy-3-[N-(2-chloro-l ,3,4-thiadiazol-5-yl)- 245.8 carbamoyl]coumarin (dec) 40 3-[N-(4-chloro-6-methylpyrimidin-2-yl)carbamoyl]4- 207.7 hydroxycoumarin 41 3-[N-(6-chloropyrazin-2-yl)carbamoyl]-4-hydroxycoumarin 260.4 42 3-[N-(4,6-dichloropyrimidin-5-yl)carbamoyl]-4-hydroxy- 201.1 coumarin 43 3-[N-(3,6-dichloropyridazin-4-yl)carbamoyl]-4-hydroxy- 214.5 coumarin 44 4-hydroxy-3-[N-[5-(2 -fluorophenyl)- 1, 3, 4-thiadiazol-2- 250.8 yl ] carbamoyl] coumarin 45 7-phenyl-4-hydroxy-3-[N-[5-(trifluoromethyl)-l,3,4-thia- 214.5 diazol-2-yl]caramoyl]coumarin (dec) 46 3-[N-(4-bromophenyl)carbamoyl]-7-phenyl-4-hydroxy- 218.9 coumarin 47 3-[N-(5-bromopyridin-2-yI)carbamoyl]-4-hydroxycoumarin 228.1 48 3-[N-(2-pyridinyl)carbamoyl]-4-hydroxycoumarin 236.2 49 3-[N-(5-chloropyτidin-2-yl)carbamoyl]-4-hydroxycoumarin 242.8 50 3-[N-(2-chloropyridin-3-yl)carbamoyl]-4-hydroxycoumarin 222.1 51 3-[N-(5-methylpyridin-2-yr)carbamoyl]-4-hydroxycoumarin 246.5 52 3-[N-(6-methoxypyridin-3-yl)carbamoyl]-4-hydroxy- 195.2 coumarin 53 7-trifluoromethyl-3-[N-[4-(2,4-difluoro)phenyl]]-4- 202.4 hydroxycoumarin 54 7-bromo-3-[N-[4-chlorophenyl)carbamoyl]-4-hydroxy- 233.6 coumarin 55 3-[N-(3,5-dichloropyridin-2-yl)carbamoyl]-4-hydroxy- 242.1 coumarin 56 3-[N-(5-bromopyridin-2-yl)carbamoyl]-7-chloro-4- 240.9 hydroxycoumarin 57 7-bromo-3-[N-(4-tert-butylphenyl)carbamoyl]-4-hydroxy- 228.3 coumarin 8 7-bromo-3-[N-[4-(2,4-difluoro)phenyl]carbamoyl]-4- 223.2 hydroxycoumarin (dec) 59 7-bromo-3-[N-(4-cyanophenyl)carbamoyl]-4-hydroxy- 266.0 coumarin 60 3-[N-[5-( l . l -dimethylethyl)-l ,3,4-thiadiazol-2- 241.2 yl)carbamoyl]-4-hydroxycoumarin 61 3-[N-(5-bromopyridin-2-yl)carbamoyl]-7-methyl-4- 240.8 hydroxycoumarin 62 7-bromo-3-[N-(4-fluorophenyl)carbamoyl]-4-hydroxy- 218.1 coumarin 63 3-[N-(2,3,5,6-tetrafluoropyridin-4-yl)carbamoyl]-6- 186.9 methoxy-4-hydroxycoumarin 64 7-chloro-3-[N-(5-chloropyridin-2-yl)carbamoyl]-4- 241.5 hydroxycoumarin 65 7-chloro-3-[N-(5-chloropyridin-2-yl)carbamoyl]-4- 210.9 hydroxycoumarin, triethylamine salt 66 7-bromo-3-[N-(4-trifluoromethylphenyl)carbamoyl]-4- 234.2 hydroxycoumarin 67 7-fluoro-3-[N-(5-bromopyridin-2-yl)carbamoyl]-4-hydroxy- 205.4 coumarin 68 7-chloro-3-[N-(3-chloro-5-trifluoromethylpyridin-2-yl)- 252-254 carbamoyl]-4-hydroxycoumarin 69 3-[N-(3-chloro-5-trifluoromethylpyridin-2-yl)carbamoyl]-4- 221.6 hydroxycoumarin 70 3-[N-(3,5-ditrifluoromethylpyridin-2-yl)carbamoyl]-4- 173-174 hydroxycoumarin 71 7-trifluoromethyl-3-[N-(5-bromopyridin-2-yl)carbamoyl]-4- 236.6 hydroxycoumarin 72 7-trifluoromethyl-3-[N-(5-chloropyridin-2-yl)carbamoyl]-4- 228.6 hydroxycoumarin 73 7-trifluoromethyl-3-[N-(2-chloropyridin-3-yl)carbamoyl]-4- 231.5 hydroxycoumarin 74 7-trifluoromethyl-3-[N-(6-chloropyridin-3-yl)carbamoyl]-4- 269.3 hydroxycoumarin 75 7-chloro-3-[N-(6-methoxypyridin-3-yl)carbamoyl]-4- 237.0 hydroxycoumarin 76 7-trifluoromethyl-3-[N-(6-meύιoxypyridin-3-yl)carbamoyl]- 263.4 4-hydroxycoumarin (dec) 77 7-chloro-3-[N-(2-chloropyridin-3-yl)carbamoyl]-4-hydroxy- 255.7 coumarin 78 7-chloro-3-[N-(6-chloropyridin-3-yl)carbamoyl]-4-hydroxy- 269.8 coumarin 79 7-chloro-3-[N-(3,5-ditrifluoromethylpyridin-2-yl)carba- 206-209 moy ]-4-hydroxycoumarin 80 7-trifluoromethyl-3-[N-2,3.5,6-tetrafluoropyridin-4-yl)- 166.8 carbamoy 1 ] -4-hydroxy coumarin 81 7-chloro-4-hydroxy-3-[N-[5-(l,l,2.2,3,3,3-heptafluoro- 218.7 propyl)- 1, 2, 4-thiadiazol-2-yl]carbamoyl]coumarin 82 3-[N-(4-benzoylphenyl)carbamoyl]-4-hydroxycoumarin 210.7 83 3-[N-(4-phenylhydroxymethylphenyl)carbamoyl]-4- 196-199 hydroxycoumarin 84 7-chloro-3-[N-(4-phenylhydroxymethylphenyl)carbamoyl]- 212-214 4-hydroxycoumarin (dec) 85 7-chloro-4-hydroxy-3-[N-[4-(l , l-trifluoromethyl-l- 218.5 hydroxymedιyl)phenyl] carbamoyl]-4-hydroxycoumarin 86 3-[N-[4-trifluoromethylphenyl)carbamoyl]-4-hydroxy- 260.2 coumarin 87 7-trifluoromethyl-3-[N-[4-trifluoromethylphenyl)- 218.4 carbamoyl]-4-hydroxycoumarin 88 7-trifluoromethyl-3-[N-[4-trifluoromethoxyphenyl)- 202.2 carbamoyl]-4-hydroxycoumarin 89 7-chloro-3-[N-[4-trifluoromethoxyphenyl)carbamoyl]-4- 248.2 hydroxycoumarin 90 3-[N-[4-(trifluoromethoxyphenyl)carbamoyl]-4-hydroxy- 208.8 coumarin 91 7-bromo-3-[N-[4-bromophenyl)carbamoyl]-4-hydroxy- 240.5 coumarin The 3-carbamoyl-4-hydroxycoumarins of this invention (Formula I) are effective against parasitic worms, particularly those of valuable domestic warm-blooded animals and more particularly helminth parasites in ovines (sheep) and bovines (cattle). Although a significant number of the 3-carbamoyl-4-hydroxycoumarins have failed to demonstrate significant activity against Caenorhabditis elegans in vitro, observations in Jirds, Meriones unpuiculatus. infected with Haemonchus contortus in accordance with the procedure described in J. Parasitol. 76(2), 1990, p. 168-170, generally confirm anthelmintic activity as set forth in Table I. In addition, various 3-carbamoyl-4-hydroxycoumarins have been tested for in vivo activity against the hookworm, Nematospiroides dubius. of mice in accordance with Procedure I and the results set forth in Table II. Further observations in sheep experimentally infected with Haemonchus contortus in accordance with Procedure II, confirm anthelmintic activity as set forth in Table III. Procedure I Mice are infected with N. dubius. Each mouse is given — 100 infective larvae of H- dubius per os. Two weeks later mice from each community cage are sacrificed and examined for the presence of hookworms. Following sampling, the remaining animals are randomly allotted to treated groups of five mice/group. Throughout the experiments mice receive food and water ad libitum. Method A (Oral Administration) Test compounds are evaluated orally in five mouse groups at the following dosage: Oral treatments are administered with a 1 cc tuberculin syringe fitted with a cannula. Each mouse receives 1/4 of the test dose/day on four consecutive days in 0.1 ml of vehicle (40% glycerol formal, 5% polyvinylpyrrolidone C-15 in propylene glycol). In each separate experiment ten mice are used as non-treated controls. Method B (Drug in Feed) The feed containing test compound is weighed and randomly allotted to the cages that will house each group of mice for the duration of the trial (6 days). The food is contained in a controlled access feeder. Food and water are available to the mice ___{ libitum. Th e following doses are used for test compound: All mice in each trial are sacrificed three days after the last treatment and examined for N. dubius. The clearance rate is calculated according to the following formula: number of mice cleared Clearance rate = x 100 number of mice treated Procedure II In individual experiments all sheep are treated identically, however non-critical variations occur between experiments. All of the sheep used in this procedure are treated twice with levamisole hydrochloride orally at 8 mg/kg or once each with ivermectin parenterally at 200 μg/kg and levamisole hydrochloride orally at 8 mg/kg. The second treatment in each case is administered 4-7 days after the first treatment. Two weeks after the second treatment all sheep are inoculated per QS with — 3,500 to — 7,500 infective larvae of H. contortus. Rectal fecal samples are taken from each sheep 26-41 days post-inoculation (PIj, and these samples are examined for eggs of H. contortus using the McMaster counting chamber technique. All sheep harboring good infections of H. contortus are randomly allocated to a treatment group; those which do not exhibit suitable infections are dropped from the study. One-three days later on days 27-42 PI each sheep remaining in the study (excluding the non-treated controls) is treated with a test compound (orally at 12.5 mg/kg unless indicated otherwise) or a standard (levamisole hydrochloride orally at 8 mg/kg) or is used as an untreated control. All sheep receive food and water ad. lit- throughout the experiment. Prior to administration, all solid compounds are finely ground using a mortar and pestle. The compounds are suspended in 20-30 ml of sterile vehicle #98 (each ml contains: carboxymethylcellulose - 10 mg, polysorbate 80-4 mg, propylparaben - 0.42 mg) using a sonicator and administered along with a tap water wash via a stomach tube. All test compounds are given to a single sheep/route of administration. Two or more sheep are treated with levamisole hydrochloride and five are used as nontreated controls. All animals are monitored for signs of toxicity following treatment. The sheep are sacrificed 7-12 days after treatment (days 35-49 PI), and the abomasum is ligated and removed from each sheep. Each abomasum is longitudinally sectioned and rinsed into an 80 mesh sieve. Sieve contents are collected in individual containers and fixed in formol- alcohol. Later each sample is transferred to a 1000 or 2000 ml beaker and the volume brought to 400-1000 ml with tap water. The total number of worms in a 40-100 ml aliquot (10%) is determined. When no worms are found in the 10% aliquot, the entire sample is examined. Total worm number/sheep and percentage clearance for each treatment are calculated. Percentage clearance for a particular test compound in a given trial is determined according to the following formula: Percentage Clearance (Test Compound) = [(Mean number of worms recovered from nontreated control sheep - Number of worms recovered from treated sheep)/Mean number of worms recovered from nontreated control sheep] x 100. Sheep which die within 24 hr following treatment are not examined for worms, while any that die between 24 hr post-treatment and necropsy are examined in an identical manner as that described above. The results of various trials are combined and reported in Table III as percentage clearance. In addition, various 3-carbamoyl-4-hydroxycoumarins have been tested for in vivo anticoccidial activity against die coccidian parasite, Eimeria tenella, in chickens in accordance with Procedure III and the results set forth in Table IV. Procedure III Procedures for Handling Birds: One-day-old Leghorn or Leghorn-Broiler cross cockerals are placed in Petersime brood- units (25 birds per section) where they are reared under continuous light and at approximately 75°F for two weeks. Feed (diet P-607) and water are available ad libitum. When birds are two weeks old, the number required for a trial are moved to the screening rooms which have continuous light and are maintained at 75°F. A separate feed supply is available in each cage; water is available behind each row of cages. Birds are checked daily and the floors are washed. When a trial is terminated, cages and waterers are washed with a high-pressure sprayer. Preparation of Test Samples: Test compounds are initially evaluated at 400-500 ppm technical material in the feed. To prepare a sample for testing, a small amount of test sample is mixed in a few gm of fine feed (60 mesh screen) and then ground with a mortar and pestle to make a premix. This sample is mixed with additional feed on a batch mixer. Coban (Eli Lilly) containing 45 gm monensin as monensin sodium per lb is the currently used standard. It is included in the feed at a technical drug concentration of 121 ppm. Test Procedures: Each experimental unit consists of three birds in a single cage. A completely random experimental design widi one replicate is used. There are four groups of birds. Group 1 is an environmental control; these birds receive non-medicated feed (diet P-607) and are not infected. Group 2 is a positive control; these birds are artificially infected widi sporulated oocysts and are fed a diet containing a commercial anticoccidial. Group 3 is an infected control; these birds are infected widi sporulated oocysts and receive non-medicated fee. Group 4 represents test birds; these birds are infected with sporulated oocysts and provided feed containing test samples. Birds are weighed and placed in cages and provided the appropriately medicated feed on Monday morning. Forty-eight hours later, birds are intubated with the inoculum containing sporulated oocysts of mixed populations of Eimeria acervulina, E. maxima, E. tenella. Evaluation Variables: Birds are observed throughout the test period (8 days) for mortalities, and on Day 8 scored for blood in the droppings. The scale for dropping scores is as follows: 0= normal. 1 =few loose droppings. 2=loose droppings with blood, and 3=many bloody droppings. On Day 8 of the test period (following Tuesday), birds are sacrified by cervical dislocation, weighed and the intestines scored for hemorrhagic lesions (upper intestine: E. acervulina, middle intestine: E. maxima, cecum: E. tenella) by a modified mediod of Johnson and Reid (1970). The modified scale for lesion scores is as follows: 0=no lesions, l =few lesions, 2=moderate lesions, and 3=severe lesions. Birds that die during die experiment ware weighed and scored for lesions at or near the time of death. A compound is considered active against a particular species of coccidian if the lesion scores for that species is ≤2.0. Diet: DIET P-607 FOR BIRDS Ingredients Percent Corn, coarse ground 70.5 Soybean Oil Meal, 48.5 25.0 Yellow Tallow, stabilized 1.0 Limestone 0.7 Dicalcium Phosphate (18.5%) 2.0 Salt 0.4 DL-methionione (98 %) 0.1 Vitamin D, 15,000 ICU/gm 0.006 Vitamin A, 30,000 IU/gm 0.005 Dawes 3-6-9-90 (B-vits) 0.05 Vitamin B 12 Suppl., 10 mg/lb 0.04 Trace Minerals (CCC 10% Zn) 0.05 Nutrigard - 25 (25% ethoxyguin) 0.05 DETAILED DESCRIPTION (cont'd) The 3-carbamoyl-4-hydroxycoumarins of Formula I (including IA, IA', IB, IC, IF, IG, IH, II, IJ, IK, IW, IX, IY, and IZ) can be used as die pure compounds or as mixtures of pure compounds but for practical reasons the compounds are preferably formulated as andielmintic compositions and administered as a single or multiple dose, alone or in combination with other anthelmintics (e.g. avermectins, benzimidazoles, levamisole, praziquantel, etc.). For example, aqueous or oil suspensions can be administered orally, or the compounds can be formulated widi a solid carrier for feeding. Furthermore, an oil suspension can be converted into an aqueous emulsion by mixing with water and injecting die emulsion intramuscularly, subcutaneously or into the peritoneal cavity. In addition, die active compound(s) can be administered topically to die animal in a conventional pour-on formulation. Pure compounds, mixtures of the active compounds, or combinations thereof with a solid carrier can be administered in the animal's food, or administered in die form of tablets, pills, boluses, wafers, pastes, and other conventional unit dosage forms, as well as sustained release dosage forms which deliver the active compound over an extended period of days, weeks or months. All of these various forms of the active compounds of this invention can be prepared using physiologically acceptable carriers and known methods of formulation and manufacture. Representative solid carriers conveniently available and satisfactory for physiologically acceptable, unit dosage formulations include corn starch, powdered lactose, powdered sucrose, talc, stearic acid, magnesium stearate, finely divided bentonite, and the like. The active agent can be mixed widi a carrier in varying proportions from, for example, about 0.001 percent by weight in animal feed to about 90 or 95 percent or more in a pill or capsule. In the latter form, one might use no more carrier than sufficient to bind die particles of active compound. In general, the compounds can be formulated in stable powders or granules for mixing in an amount of feed for a single feeding or enough feed for one day and thus obtain therapeutic efficacy without complication. It is the prepared and stored feeds or feed premixes that require care. A recommended practice is to coat a granular formulation to protect and preserve the active ingredient. A prepared sheep-feed containing about 0.2 percent of the active compound will provide a dosage of about 100 mg per kg body weight for each 100 lb sheep in its daily ration. A solid diluent carrier need not be a homogeneous entity, but mixtures of different diluent carriers can include small proportions of adjuvants such as water; alcohols; protein solutions and suspensions like skimmed milk; edible oils; solutions, e.g., syrups; and organic adjuvants such as propylene glycols, sorbitol, glycerol, diediyl carbonate, and the like. The solid carrier formulations of the inventions are conveniently prepared in unit dosage forms, to facilitate administration to animals. Accordingly, several large boluses (about 20 g weight) amounting to about 54 g of active compound would be required for a single dosage to a 900 lb horse at a dosage rate of 50 mg/kg of body weight. Similarly, a 60 lb lamb at a dosage rate of 100 mg/kg of body weight would require a pill, capsule, or bolus containing about 2.7 g of active compound. A small dog, on the other hand, weighing about 20 lbs. would require a total dosage of about 225 mg at a dosage rate of 25 mg/kg of body weight. The solid, unit dosage forms can be conveniently prepared in various sizes and concentrations of active ingredient, to accommodate treatment of the various sizes of animals that are parasitized by worms. Liquid formulations can also be used. Representative liquid formulations include aqueous (including isotonic saline) suspensions, oil solutions and suspensions, and oil in water emulsions. Aqueous suspensions are obtained by dispersing the active compound in water, preferably including a suitable surface-active dispersing agent such as cationic, anionic, or non-ionic surface-active agents. Representative suitable ones are polyoxyalkylene derivatives of fatty alcohols and of sorbitan esters, and glycerol and sorbitan esters of fatty acids. Various dispersing or suspending agents can be included and representative ones are synthetic and natural gums, tragacanth, acacia, alginate, dextran, gelatin, sodium carboxymethylcellulose, methylcellulose, sodium polyvinylpyr- rolidone, and d e like. The proportion of the active compound in die aqueous suspensions of the invention can vary from about 1 percent to about 20 percent or more. Oil solutions are prepared by mixing die active compound and an oil, e.g. an edible oil such as cottonseed oil, peanut oil, coconut oil, modified soybean oil, and sesame oil. Usually, solubility in oil will be limited and oil suspensions can be prepared by mixing additional finely divided compound in die oil. Oil in water emulsions are prepared by mixing and dispersing an oil solution or suspension of the active compound in water preferably aided by surface-active agents and dispersing or suspending agents as indicated above. In general, the formulations of this invention are administered to animals so as to achieve therapeutic or prophylactic levels of the active compound. Effective dosages of various compounds are contemplated, e.g., in the range of 1 to 75 mg/kg of body weight. In other animals, and for other kinds of parasitic worms, definitive dosages can be proposed. Contemplated are dosage rates of about 1 mg to about 800 mg/kg of body weight. A preferred, contemplated range of dosage rates is from about 1 mg to about 50 mg/kg of body weight. In this regard, it should be noted tiiat the concentration of active compound in the formulation selected for administration is in many situations not critical. One can administer a larger quantity of a formulation having a relatively low concentration and achieve the same therapeutic or prophylactic dosage as a relatively small quantity of a relatively more concentrated formulation. More frequent small dosages will likewise give results comparable to one large dose. One can also administer a sustained release dosage system (protracted delivery formulation) so as to provide therapeutic and/or prophylactic dosage amounts over an extended period. Unit dosage forms in accordance with this invention can have anywhere from less than 1 mg to 500 g of active compound per unit. Although the anthelmintic agents of this invention will find dieir primary use in the treatment and/or prevention of helminth parasitism in valuable warm-blooded domesticated animals such as sheep, catde, horses, dogs, swine, goats and poultry, they are also effective in treatment that occurs in other warm blooded animals including man. The optimum amount to be employed for best results will, of course, depend upon the particular compound employed, species of animal to be treated, die regimen of treatment and the type and severity of helminth infection. Generally good results are obtained ' widi compounds of Formula I by the oral or parenteral route of administration of about 1 to 300 mg/kg of animal bodyweight (such total dose being given at one time, in a protracted manner or in divided doses over a short period of time such as 1-4 days). The technique for administering these materials to animals are known to those skilled in die veterinary and medical fields. It is contemplated mat the compounds of Formula I can be used to treat various helminth diseases in humans, including tiiose caused by Ascaris. Enterobius. Ancylostoma. Trichuris. Strongyloides. Fasciola. Taenia. and/or Onchocerca or other filariae at a dose of from 1 mg/kg to 300 mg/kg of body weight upon oral and/or parenteral administration. The anticoccidial compositions of this invention containing as the active ingredient a 3- carbamoyl-4-hydroxycoumarin of Formula IW [wherein R' 2 is hydrogen, CF 3 or halogen (Cl, Br, F or I), R' is Br, F, Cl or CF 3 and R is Br, F or CF 3 ] (preferably 4-chlorophenyl, more preferably 2,4-difluorophenyl), hydrates or pharmaceutically acceptable salts are prepared by mixing die active ingredient wid an inert ingredient. The inert ingredient can comprise a feedstuff, extender materials and die like. By the term "inert ingredient" is meant a material which does not function as an antiparasitic agent, e.g., an anticoccidial, is in active with respect to the active ingredient and which may be safely ingested by d e animals to be treated, and tiros, such inert material is one which is inactive for the purpose of the present invention. The active ingredient, when orally administered to coccidiosis susceptible domestic animals, particularly fowl such as turkeys and chickens, as a component of feed, effectively controls the disease by preventing it. (Furthermore, the treated fowl either maintain their weight or actually gain weight when compared to controls. Thus, the compositions of this invention not only control coccidiosis, but also aids in improving die efficiency of conversion of feed to weight gains.) The actual concentration of the active ingredient in animal feed can, of course, be adjuste to the individual needs and may vary over a wide range. The limiting criteria of the concentratio are that the minimum concentration is such that a sufficient amount of active ingredient is provided to effect the desired control of coccidiosis and the maximum concentration is such tiiat the amoun of composition ingested does not result in any untoward or undesirable side effects. Thus, for example, a feed premix or complete feed contains sufficient active ingredient to provide from about 1 ro 250 ppm in feed. The optimum dose level will, of course, vary with die size of the animal. When using the antibiotics in accordance with the invention for treating or preventing coccidiosis, it can be first compounded or blended widi a feed ingredient or carrier to become a feed additive premix, a feed concentrate, or a feed additive supplement. A feed additive, concentrate or premix is an article intended to be diluted to produce a complete feed, i.e., an article intended to be administered as a sole ration. A feed additive supplement is an article intended for consumption by an animal directly or which can be further diluted to produce a complete feed or can be ingested and used as a supplement to otiier rations. Feed additive supplements, concentrates and premixes contain the active ingredient to a suitable carrier and mixing in a manner to give substantially uniform dispersion of the anticoccidial in the carrier. Suitable carriers are solids that are inert with respect to the active ingredient and which may safely be ingested by the animals to be treated. Typical of such carriers are commercial poultry feeds, ground cereal grains, grain by-products, plant protein concentrates (soy, peanuts, et.), fermentation by-products, salts, limestone, inorganic compounds, and the like or admixtures tiiereof. Liquid dispersions can be prepared by using water or vegetable oil preferably including a surface active agent, emulsifying agent, and die like, in the liquid dispersion such as ethylenediaminetetraacetic acid, etc., and solubilizers. Any suitable carrier or extender material can function as the inert ingredient in the solid form of the antiparasitic agent provided that it is inert to the active material and is non-toxic insofar as the animal to which it is to be administered is concerned. The active ingredient may be blended into a mesh, pellet, or any desired configuration with the inert carrier or extender solid material by any convenient technique. For example, compositions can be found by finely grinding or pulverizing the active ingredient and the inert ingredient using any commercially available grinder or pulverizer with or without the feed material being present. If the feed material is not present when the grinding or pulverizing is effected, the resultant material can be distributed, in accordance with the present invention, in any conveniendy available feed material. Typically, poultry feeds which can be medicated with the active ingredient of this invention can contain several ingredients; for example, they can contain high energy grain products such as corn, wheat, wheat red dog flour, milo, oatmeal, or the like; medium and low _τ>. energy grain products, such as oats, barley, wheat flour, middlings, standard middlings or the like; stabilized fats; vegetable protein such as soybean meal, corn gluten meal, peanut meal, or die like; animal protein such as fish meal, fish solubles, meat scraps or the like; UGF (Unidentified Growth Factor) sources and otiier B-vitamin carriers such as dried milk products, dried brewers yeast, distillers dried solubles, fermentation solubles, or the like; dehydrated alfalfa meal; and various special additives such as additional riboflavin. vitamin B 12 , calcium pantodienate. niacin. choline. vitamin K and vitamin E or the like, as well as stabilized vitamin A, vitamin D 3 (D-activated animal sterols): calcium and phosphorus supplements such as dicalcium phosphate, steamed bone meal, defluorinated phosphate, limestone, or the like; iodized salt, manganese sulfate, zinc carbonate, an antibiotic feed supplement; methionine or its hydroxy analog, and die antioxidant. As is evident from the above, the anticoccidial compositions are intended for oral ingestion. They can be added to the normal feed supply of the treated animal or can be administered by other procedures, such as incorporating the same in a tablet, pill or bolus and supplying it forcibly to the animal. The administration of the active ingredient must be considered in terms of the specific animal under the husbandry practices encountered. FORMULAE 10 IA 20 25 '; IB 35 IC 10 20 IG IE 10 II 20 IJ II 10 TT 20 25 30 IX 35 r>', 10 15 20 25 IW SPECIFIC FORMULAE 10 Cpd 6 Cpd 8 Cpd L7 Cpd 11 20 Cpd IS Cpd 53 Cpd 54 CHART A Scheme A Scheme B. 3 Et,N Xylene CHART B TABLE I TABLE II TABLE III TABLE IV

Claims: CLAIMS 1. A compound, hydrate diereof or pharmaceutically acceptable salt thereof of the formula: - wherein X is selected from the group consisting of (1) 4-halophenyl (A); (2) 4-R 4 phenyl (A') (3) (5-R' 5 )-l,3,4-thiadiazol-2-yl (B); (4) (2-SR" 5 )-l,3,4-thiadiazol-5-yl (C); (5) pyridin-2-yl (X) (6) pyridin-3-yl (Y) (7) pyridin-4-yl (Z) (8) pyrimidin-5-yl (F): (9 pyrazin-2-yl (G); (10) pyrimidin-2-yl (H); (11 ) -NH-phenyl (I): (12) 4~[di(C j -C5)alkoxyphosphonomethyl]phenyl (J); or (13) 4-(pyridin-4-ylmedιyl)phenyl (K); wherein the variable substituents (1) and (2) are optionally substituted at die 2 position of the phenyl moiety with halogen (Cl, Br, F, or I); wherein the variable substituents (5)-(ll) are optionally substituted widi one, two or three members selected from d e group consisting of halogen (Cl, Br, F or I), CN, CF 3 , CyC^ alkyl or 0^5 alkoxy; wherein the variable substituent (13) is optionally substituted in the pyridinyl moiety with one or two members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C j - C5 alkyl or C j -Cs alkoxy; wherein R is selected from the group consisting of hydrogen, phenyl, halogen (Cl, Br, F or I), CN, CF 3 , C j -Cs alkyl or C^ alkoxy, widi die proviso that when X is 4-halophenyl (A), R is Cl, F, Br, CF 3 or phenyl; wherein R is selected from cyano (-C*N), trifluoromediyl, C C4 alkyl, phenylhydroxymethyl (-CHOH-phenyl), hexafluoro-2-hydroxyisopropyl (-C(CF 3 ) 2 OH), or trifluoromethoxy (-O-CF3). wherein R' 5 is selected from a halogen (Cl, Br, F, or I) atom, cyano. -CF 3 , -CF2CI. -CF 2 CF 3 . benzyl, benzyl substituted widi [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN. CF 3 , C -C ζ alkyl or C j -C 5 alkoxy], pyridin-2- yl, pyridin-2-yl substituted widi [one, two or three members selected from the group consisting or halogen (Cl, Br, F or I), CN, CF 3 , C r C 5 alkyl or C r C 5 alkoxy], pyridinr3-yl, pyridin-3-yl substituted widi [one, two or tiiree members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , ^^5 alkyl or C^-C ζ alkoxy], pyridin-4-yl, pyridin-4-yl substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN. CF 3 , C r C 5 alkyl or C r C 5 alkoxy]; wherein R" 5 is selected from hydrogen, Cι~C 5 alkyl, halogen (Cl, Br, F, or I), cyano, - CF 3 , -CF 2 C1, -CF 2 CF 3 , phenyl, phenyl substituted widi [one, two or three members selected from die group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C j -C5 alkyl or C^Cs alkoxy], benzyl, benzyl substituted widi [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C r C 5 alkyl or C r C 5 alkoxy], pyridin-2-yl, pyridin-2-yl substituted widi [one, two or three members selected from the group consisting of halogen (Cl. Br, F or I), CN, CF 3 , C r C 5 alkyl or C C 5 alkoxy], pyridin-3-yl, pyridin-3-yl substituted widi [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C j -C5 alkyl or C1-C5 alkoxy], pyridin-4-yl, pyridin-4-yl substituted widi [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C C5 alkyl or C j -C 5 alkoxy]; pyridin-2-yl(CH 2 )-, pyridin-2-yl(CH 2 )- substituted widi [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C1-C5 alkyl or C j -Cs alkoxy], pyridin-3-yl(CH 2 )-, pyridin-3-yl(CH 2 )- substituted widi [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C^Cs alkyl or C j -C 5 alkoxy], pyridin-4-yl(CH 2 )-, pyridin-4-y CH^- substituted widi [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C j -C5 alkyl or C j -05 alkoxy]; or hydrates or a pharmaceutically acceptable salt thereof; other than: 3-[N-[4-trifluoromethylphenyl)carbamoyl]-4-hydroxycoumarin, 3-[N-[4-trifluoromethoxyphenyl)carbamoyl]-4-hydroxycoumarin 3-[N-(5-benzyl-l,3,4-thiadiazol-2-yl)carbamoyl]-7-chloro-4-hydroxycoumarin, 7-chloro-4-hydroxy-3-[N-[5-(2-pyridinylmethyl)thio-l ,3,4-thiadiazol-5- yl]carbamoyl]coumaτin, 7-chloro-4-hydroxy-3-[N-(5-phenyI-l,3,4-dιiadiazol-2-yl]carbamoyl]coumarin, 3-[N-(2-(benzylthio- 1.3 ,4-thiadiazol-5-yl)carbamoyl]-7-chloro-4-hydroxycoumarin, 3-[N-(3,6-dichloropyridazin-4-yl)carbamoyl]-4-hydroxycoumarin, 4-hydroxy-3-[N-(2-pyridinylcarbamoyl)courmarin, 4-hydroxy-3-[N(3-pyridinylcarbamoyl)courmarin, 7-trifluoromethyl-3-[N-(3-chloro-5-trifluorornethylpyridin-2-yl)carbamoyl]-4- hydroxycoumarin, 3-[N-(6-chloropyridin-3-yl)carbamoyl]-4-hydroxycoumarin, 3-[N-(6-methylpyridin-2-yI)carbamoyl]-4-hydroxycoumarin, 3-[N-(5-bromopyridin-2-yl)carbamoyl]-7-methoxy-4-hydroxycoumarin, or 3-[N-(2,6-dichloropyridin-4-yl)carbamoyl]-4-hydroxycoumarin. 2. A compound according to Claim 1 wherein X is 4-halophenyl and the compound, hydrate or pharmaceutically acceptable acid addition salt thereof is a 3-[N-(4-halophenyl)carbamoyl]-4- hydroxycoumarin (IA). 3. A compound according to Claim 2 wherein the compound or hydrate thereof is selected from the group consisting of 3-[N-(4-bromophenyl)carbamoyl]-7-chloro-4-hydroxycoumarin; 3-[N- (4-bromoph enyl)-carbamoyl] -7 -tr if luoromethyl-4-hydroxy coumarin; 3-[N-(4- bromophenyl)carbamoyl]-7-fluoro-4-hydroxycoumarin; 3-[N-(4-chlorophenyl)carbamoyl]-7- chloro-4-hydroxycoumarin; 3-[N-(4-chlorophenyl)carbamoyl]-7-trifluoromethyl-4- hydroxycoumarin; 3-[N-(4-chlorophenyl)carbamoyl]-7-fluoro-4-hydroxycoumarin; 3-[N-(4- fluorophenyl)carbamoyl]-7-chloro-4-hydroxycoumarin; 3-[N-(4-fluorophenyl)carbamoyl]-7- trifluoromethyl-4-hydroxycoumarin; and 3-[N-(4-fluorophenyl)carbamoyl]-7-fluoro-4- hydroxycoumarin, or a pharmaceutically acceptable salt of any of the foregoing compounds. 4. A compound according to Claim 1 wherein X is (5-R' 5 )-l,3,4-thiadiazol-2-yl and die compound, hydrate or pharmaceutically acceptable acid addition salt thereof is a 4-hydroxy-3-[N- [5-(R' 5 )-l,3,4-thiadiazol-2-yI]carbamoyl]coumarin (IB). 5. A compound according to Claim 4 wherein the l,3,4-thiadiazol-2-yl moiety is substituted at d e 5 position with a member selected from die group consisting of trifluoromethyl, halogen, - CN, C j -C5 alkyl, benzyl optionally substituted with [one member selected from the group consisting of halogen, -CN or trifluoromeύiyl], or pyridinyl optionally substituted witii [one member selected from die group consisting of halogen, -CN or trifluoromethyl]. 6. A compound according to Claim 4 wherein die 4-hydroxy-3-[N-[5-(R'5)-l ,3,4-thiadiazol-2- yl] carbamoyljcoumarin (IB) is substituted in d e 7-position with a member selected from the group consisting of halo (Cl, Br, or F) or CF 3 . 7. A compound according to Claim 4 selected from the group consisting of: 3-[N- 4-bromophenyl)carbamoyl]-7-chloro-4-hydroxycoumarin (Cpd. #1), 3-[N-(4-bromophenyl)carbamoyl]-7-trifiuoromethyl-4-hydroxycoumarin (Cpd. #2), 3-[N-(4-bromophenyl)carbamoyl]-7-fluoro-4-hydroxycoumarin (Cpd. #3), 7-chloro-4-hydroxy-3-[N-[5-(trifluoromediyl)-l,3,4-thiadiazol-2-yl]carbamoyl]coumarin (Cpd #11), 7-chloro-4-hydroxy-3-[N-[5-(chlorodifluoromethyl)-l,3,4-thiadiazol-2-yl]carba- moyljcoumarin (Cpd #17), 7-chloro-4-hydroxy-3-[N-[5-(trifluoromethyldifluoromethyl)-l,3,4-thiadiazol-2- yl] carbamoyljcoumarin (Cpd #18), or a pharmaceutically acceptable salt of any of the foregoing compounds. 8. A compound according to Claim 1 selected from the group consisting of: 3-[N-(4-bromophenyl)carbamoyl]-7-chloro-4-hydroxycoumarin (Cpd. #1), 3-[N-(4-bromophenyl)carbamoyl]-7-trifluoromethyl-4-hydroxycoumarin (Cpd. #2), 3-[N-(4-bromophenyl)carbamoyl]-7-fluoro-4-hydroxycoumarin (Cpd. #3), 3-[N-(4-chlorophenyl)carbamoyl]-7-chloro-4-hydroxycoumarin (Cpd. #4), 3-[N-(4-chlorophenyl)carbamoyl]-7-trifluoromedιyl-4-hydroxycoumarin (Cpd. #5), 3-[N-(4-chlorophenyl)carbamoyl]-7-fluoro-4-hydroxycoumarin (Cpd. #6), 3-[N-(4-fluorophenyl)carbamoyl]-7-chloro-4-hydroxycoumarin (Cpd. #7), 3-[N-(4-fluorophenyl)carbamoyl]-7-trifluoromethyl-4-hydroxycoumarin(Cpd.#8),3-[N-(4- fluorophenyl)carbamoyI]-7-fluoro-4-hydroxycoumarin (Cpd. #9), 7-chloro-4-hydroxy-3-[N-[5-(trifluoromediyl)-l,3,4-tiiiadiazol-2-yl]carbamoyl]coumarin (Cpd. #11), 4 ιydroxy-3-[N-[5-(trifluoromeu yl)-l,3,4-thiadiazol-2-yl]carbamoyl]coumarin (Cpd. #12), 4-hydroxy-7-methyl-3-[N-5-(trifluoromedιyl)-l,3,4-thiadiazol-2-yl]carbamoyl]coumarin (Cpd. #13), 4-hydroxy-7-methoxy-3-[N-[5-(trifluoromethyl)- 1 ,3 ,4-thiadiazol-2-yl] carbamoyljcoumarin (Cpd. #14), 7-fluoro-4-hydroxy-3-[N-[5-(trifluoromeuiyl)-l,3,4-thiadiazol-2-yl]carbamoyl]coumarin (Cpd. #15), 7-trifluoromethyl-4-hydroxy-3-[N-[5-(trifluoromethyl)-l ,3,4-thiadiazol-2- yl]carbamoyl]coumarin (Cpd. #16), 7-chloro-4-hydroxy-3-[N-[5-(chlorodifluoromethyl)-l ,3,4-thiadiazol-2-yl]carba- moyl]coumarin (Cpd. #17), 7-chloro-4-hydroxy-3-[N-[5-(trifluoromethyldifluoromethyl)-l ,3,4-thiadiazol-:- yl]carbamoyljcoumarin (Cpd. #18), 4-hydroxy-3-[N-[5-(trifluoromethyldifluoromethyl)- 1 ,3, 4-thiadiazol-2-yl] car¬ bamoyljcoumarin (Cpd. #19), 7-fluoro-4-hydroxy-3-[N-[5-(trifluoromethyldifluoromethyl)-l ,3,4-thiadiazol-2- yl]carbamoyl]coumarin (Cpd. #20), 4-hydroxy-3-[N-(5-phenyl- 1 ,3 ,4-thiadiazol-2-yl)carbamoylJ coumarin (Cpd . #21), 3-[N-(6-chloropyridazin-3-yl)carbamoyl]-4-hydroxycoumarin (Cpd. #22), 3-[N-(5-benzyl-l,3,4-thiadiazol-2-yl)carbamoyl]-4-hydroxycoumarin (Cpd. #23), 3-[N-(5-benzyl-l,3,4-thiadiazol-2-yl)carbamoylJ-4-hydroxy-7-medιylcoumarin (Cpd. #24), 3-[N-[5-(4-chlorophenyl)methyl-l,3,4-thiadiazol-2-yl]carbamoylJ-4-hydroxycoumarin (Cpd. #25), 7-chloro-3-[N-[5-(4-chlorophenyl)methyl-l ,3,4-thiadiazol-2-yl]carbamoyl]-4- hydroxycoumarin (Cpd. #26), 3-[N-[2-[(4-fluorophenyl)methyl]thio-l,3,4-thiadiazol-5-yl]carbamoylJ-4-hydroxycoumarin (Cpd. #27), 4-hydroxy-3-[N-(2-mercapto-l ,3,4-thiadiazol-5-yl)carbamoyl]coumarin (Cpd. #28), 4-hydrdoxy-3-[N-[2-(medιyldιio)-l,3,4-dιiadiazol-5-ylJcarbamoyl]coumarin (Cpd. #29), 4-hydroxy-3-[N-[5-(3,5-dichloropyridin-2-yl)thio-l,3,4-thiadiazol-2-yl]carbamoyl]coumarin (Cpd. #30), 4-hydroxy-3-[N-[2-(2-pyridinylmediyl)thio-l,3,4-thiadiazol-5-ylJcarbamoyl]coumarin (Cpd. #31), 4-hydroxy-7-methyl-3-[N-[2-(2-pyridinylmethyl)thio- l ,3 ,4-thiadiazol-5- yl] carbamoyljcoumarin (Cpd. #32), 3-[N-[2-(4-pyridinylmethyl)tiiio-l,3,4-thiadiazol-5-yl]carbamoyl]4-hydroxycoumarin (Cpd. #33), 3-[N-[2-(benzylthio)-l,3,4-thiadiazol-5-yl]carbamoyl]-4-hydroxycoumarin (Cpd. #34), 3-[N-(5-bromopyrimidin-2-yl)carbamoyl]-4-hydroxycoumarin (Cpd. #35), 4-hydroxy-3-[N-(phenylamino)carbamoyl]coumarin (Cpd. #36), 4-hydroxy-3-[N-[(4-bromophenyl)amino]carbamoyl]coumarin (Cpd. #37), 4-hydroxy-3-[N-(2-bromo-l,3,4-thiadiazol-5-yl)carbamoyI]coumarin (Cpd. #38), 4-hydroxy-3-[N-(2-chloro-l ,3.4-thiadiazol-5-yl)carbamoyl]coumarin (Cpd. #39), 3-[N-(4-chloro-6-medιylpyrimidin-2-yl)carbamoyl]-4-hydroxycoumarin (Cpd. #40), 3-[N-(6-chloropyrazin-2-yl)carbamoylJ-4-hydroxycoumarin (Cpd. #41), 3-[N-(4,6-dichloropyrimidin-5-yl)carbamoyl]-4-hydroxycoumarin (Cpd. #42), 4-hydroxy-3-[N-[5-(2-fluorophenyl)-l,3.4-thiadiazol-2-yl]carbamoyl]coumarin(Cpd.#44), 7-phenyl-4-hydroxy-3-[N-[5-(trifluoromethyl)-l,3,4-thiadiazol-2-yl]caramoyl]coumarin (Cpd. #45), 3-[N-(4-bromophenyl)carbamoyl]-7-phenyl-4-hydroxycoumarin (Cpd. #46), 3-[N-(5-bromopyridin-2-yl)carbamoyl]-4-hydroxycoumarin (Cpd. #47), 3-[N-(2-pyridinyl)carbamoyl]-4-hydroxycoumarin (Cpd. #48), 3-[N-(5-chloropyridin-2-yl)carbamoyl]-4-hydroxycoumarin (Cpd. #49), 3-[N-(2-chloropyridin-3-yl)carbamoyl]-4-hydroxycoumarin (Cpd. #50), 3-[N-(5-methylpyridin-2-yl)carbamoyl]-4-hydroxycoumarin (Cpd. #51), 3-[N-(6-methoxypyridin-3-yl)carbamoylJ-4-hydroxycoumarin (Cpd. #52), 7-trifluoromethyl-3-[N-[4-(2,4-difluoro)phenyl]]-4-hydroxycoumarin (Cpd. #53), 7-bromo-3-[N-[4-chlorophenyl)carbamoyI]-4-hydroxycoumarin (Cpd. #54) , 3-[N-(3,5-dichloropyridin-2-yl)carbamoyl]-4-hydroxycoumarin (Cpd. #55), 3-[N-(5-bromopyridin-2-yl)carbamoyl]-7-chloro-4-hydroxycoumarin (Cpd. #56), 7-bromo-3-[N-(4-tert-butylphenyI)carbamoylJ-4-hydroxycoumarin (Cpd. #57), 7-bromo-3-[N-[4-(2,4-difluoro)phenyl]carbamoyl]-4-hydroxycoumarin (Cpd. #58), 7-bromo-3-[N-(4-cyanophenyl)carbamoyl]-4-hydroxycoumarin (Cpd. #59), 3-[N-[5-(l,l-dimedιyledιyl)-l,3,4-thiadiazol-2-yl)carbamoyl]-4-hydroxycoumar ' m (Cpd. #60), 3-[N-(5-bromopyridin-2-yI)carbamoyl]-7-methyl-4-hydroxycoumarin (Cpd . #61), 7-bromo-3-[N-(4-fluorophenyl)carbamoyl]-4-hjdroxycoumarin (Cpd. #62), 3-[N-(2,3,5,6-tetrafluoropyridin-4-yl)carbamoyl]-6-methoxy-4-hydroxycoumarin (Cpd. #63), 7-chloro-3-[N-(5-chloropyridin-2-yl)carbamoyl]-4-hydroxycoumarin (Cpd. #64), 7-chloro-3-[N-(5-chloropyridin-2-yl)carbamoyl]-4-hydroxycoumarin, ttiethylamine salt (Cpd. #65), 7-bromo-3-[N-(4-trifluoromediylphenyl)carbamoyl]-4-hydroxycoumarin (Cpd. #66), 7-fluoro-3-[N-(5-bromopyridin-2-yl)carbamoyl]-4-hydroxycoumarin (Cpd. #67), 7-chloro-3-[N-(3-chloro-5-trifluoromethylpyridin-2-yl)carbamoyl]-4-hydroxycoumarin (Cpd. #68), 3-[N-(3-chloro-5-trifluoromediylpyridin-2-yl)carbamoyl]-4-hydroxycoumarin (Cpd. #69), 3-[N-(3,5-ditrifluoromethylpyridin-2-yl)carbamoyl]-4-hydroxycoumarin (Cpd. #70), 7-trifluoromemyl-3-[N-(5-bromopyridin-2-yl)carbamoyl]^-hydroxycoumarin (Cpd. #71), 7-trifluoromethyl-3-[N-(5-chloropyridin-2-yl)carbamoyl]-4-hydroxycoumarin (Cpd. #72), 7-trifluoromethyl-3-[N-(2-chloropyridin-3-yl)carbamoyl]-4-hydroxycoumarin (Cpd. #73), 7-trifluoromethyl-3-[N-(6-chloropyridin-3-yl)carbamoyl]-4-hydroxycoumarin (Cpd. #74), 5 . 7-chioro-3-[N-(6-methoxypyridin-3-yl)carbamoyl]-4-hydroxycoumarin (Cpd. #75). 7-trifluoromethyl-3-[N-(6-methoxypyridin-3-yr)carbamoyl]-4-hydroxycoumarirϊ'Cpd 76), 7-chloro-3-[N-(2-chIoropyridin-3-yl)carbamoyl]-4-hydroxycoumarin (Cpd. #77). 7-chloro-3-[N-(6-chloropyridin-3-yl)carbamoyl]-4-hydroxycoumarin (Cpd. #78). 7-chloro-3-[N-(3,5-ditrifluoromethylpyridin-2-yl)carbamoyl]-4-hydroxycoumarin (Cpd. 0 #79), 7-trifluoromethyl-3-[N-2,3,5,6-tetrafluoropyridin-4-yl)carbamoyl]-4-hydroxycoumarin (Cpd. #80), 7-chloro-4-hydroxy-3-[N-[5-(l, 1,2, 2,3,3.3-heptafluoropropyl)-l,2,4-thiadiazol-2- yl]carbamoyl]coumarin (Cpd. #81), 3-[N-(4-benzoylphenyl)carbamoyl]-4-hydroxycoumarin (Cpd. #82), 3-[N-(4-phenylhydroxymethylphenyl)carbamoyl]-4-hydroxycoumarin (Cpd. #83), 7-chloro-3-[N-(4-phenylhydroxymedιylphenyl)carbamoyl]-4-hydroxycoumarin(Cpd.#84), 7-chloro-4-hydroxy-3-[N-[4-(l,l-trifluoromethyl-l-hydroxymetiιyl)phenyl]carbamoylJ-4- hydroxycoumarin (Cpd. #85), 7-trifluoromethyl-3-[N-[4-trifluoromediylphenyI)carbamoyl]-4-hydroxycoumarin (Cpd. #87). 7-trifluoromethyl-3-[N-[4-trifluoromethoxyphenyl )carbamoyl]-4-hydroxycoumarin (Cpd . #88), 7-chloro-3-[N-[4-trifluoromedioxyphenyl)carbamoyl]-4-hydroxycoumarin (Cpd. #89), 7-bromo-3-[N-[4-bromophenyl)carbamoyl]-4-hydroxycoumarin (Cpd. #91), or a pharmaceutically acceptable salt or any of the foregoing compounds. 9. A compound according to Claim 1 selected from die group consisting of: 7-chloro-4-hydroxy-3-[N-[5-(trifluoromeuiyl)-l,3,4-thiadiazol-2-yl]carbamoyl]coumarin (Cpd. #11), 7-chloro-4-hydroxy-3-[N-[5-(chlorodifluoromethyl)-l,3,4-thiadiazol-2-yl]carba- moyljcoumarin (Cpd. #17), 7-chloro-4-hydroxy-3-[N-[5-(trifluoromethyl-difluoromethyl)-l,3,4-thiadiazol-2- yl]carbamoyl]coumarin (Cpd. #18), 3-[N-(4-chlorophenyl)carbamoyl]-7-fluoro-4-hydroxycoumarin (Cpd. #6), 3-[N-(4-fluorophenyl)carbamoylJ-7-trifluoromemyM-hydroxycoumarin (Cpd. #8), or a pharmaceutically acceptable salt or any of the foregoing compounds. 10. A med od of killing parasitic worms in humans and valuable warm-blooded domestic animals which comprises administering to humans or valuable warm-blooded domestic animals in need, a therapeutic or prophylactic dosage of a 3-carbamoyl-4-hydroxycoumarin, hydrate diereof, or pharmaceutically acceptable salt thereof of the formula: wherein X is selected from the group consisting of (1) 4-halophenyl (A); (2) 4-R 4 phenyl (A') (3) (5-R' 5 )-l,3,4-thiadiazol-2-yl (B); (4) (2-SR" 5 )-l,3,4-thiadiazol-5-yl (C); (5) pyridin-2-yl (X) (6) pyridin-3-yl (Y) (7) pyridin^4-yl (Z) (8) pyrimidin-5-yl (F); (9) pyrazic-2-yl (G); (10) pyrimidin-2-yl (H); (11) -NH-phenyl (Q; (12) 4-[di(C 1 -C5)alkoxyphosphonomethyl]phenyl (J); or (13) 4-(pyridin-4-ylmethyl)phenyl (K); wherein the variable substituents (1) and (2) are optionally substituted at the 2 position of the phenyl moiety with halogen (Cl, Br, F, or I); wherein the variable substituents (5)-(l 1) are optionally substituted with one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C j -C^ alkyl or C j -C5 alkoxy; wherein the variable substituent (13) is optionally substituted in the pyridinyl moiety with one or two members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C^ C 5 alkyl or C^ alkoxy; wherein R is selected from the group consisting of hydrogen, phenyl, halogen (Cl, Br, F or I), CN, CF 3 , C j -C 5 alkyl or C j -C 5 alkoxy, with the proviso that when X is 4-halophenyl (A), R is Cl, F, Br. CF 3 or phenyl; wherein R 4 is selected from cyano (-C «N), trifluoromethyl. C j -C alkyl, phenylhydroxymethyl (-CHOH-phenyl), hexaf uoro-2-hydroxyisopropyl (-C(CF 3 ) 2 OH), or trifluoromethoxy (-0-CF 3 ;. wherein R' 5 is selected from a halogen (Cl, Br, F, or I) atom, cyano. -CF 3 , -CF 2 C1. -CF 2 CF 3 , benzyl, benzyl substituted with [one. two or three members selected from the group consisting of halogen (Cl, Br. F or I), CN, CF 3 , C2-C5 alkyl or C j -C 5 alkoxy], pyridin-2- jl, pyridin-2-yl substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C r C 5 alkyl or C r C 5 alkoxy], pyridin-3-yl, pyridin-3-yl substituted widi [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C r C 5 alkyl or C r C 5 alkoxy], pyridin-4-yl, pyridin-4-yl substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C r C 5 alkyl or C r C 5 alkoxy]; wherein R" 5 is selected from hydrogen, C j -C 5 alkyl, halogen (Cl, Br, F, or I), cyano, - CF 3 , -CF 2 C1, -CF 2 CF 3 , phenyl, phenyl substituted widi [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C j -C 5 alkyl or C j -C 5 alkoxy], benzyl, benzyl substituted widi [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I). CN, CF 3 , C 2 -C 5 alkyl or C r C 5 alkoxy], pyridin-2-yl, pyridin-2-yl substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br. F or I), CN. CF 3 . C1-C5 alkyl or C1-C5 alkoxy], pyridin-3-yl, pyridin-3-yl substituted widi [one. two or three members selected from the group consisting of halogen (Cl, Br. F or I), CN, CF 3 , C2-C5 alkyl or CJ-C5 alkoxy], pyridin-4-yl, pyridin-4-yl substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , ^- ζ alkyl or C j -C alkoxy]; pyridin-2-yl(CH 2 )-, pyridin-2-yl(CH2)- substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C j -C5 alkyl or C j -C 5 alkoxy], pyridin-S-y CH^-, pyridin-S-y CH^- substituted widi [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C j -Cs alkyl or C1-C5 alkoxy], p ridin^yl CH^-, pyridin-4-yl(CH2)- substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C j -05 alkyl or C j -C5 alkoxy]; or hydrates or a pharmaceutically acceptable salt thereof; other than: 3-[N-(5-benzyl-l,3,4-thiadiazol-2-yl)carbamoyl]-7-chloro-4-hydroxycoumarin, 7-chloro-4-hydroxy-3-[N-[5-(2-pyridinylmethyl)thio-l ,3,4-thiadiazol-5- yljcarbamoyljcoumarin, 7-chloro-4-hydroxy-3-[N- 5-phenyl-l,3,4-thiadiazol-2-yl]carbamoyl]coumarin, 3-[N-(2-(benzyldιio-l,3,4-thiadiazol-5-yl)carbamoyl]-7-chlor -4-hydroxycoumarin, 3-[N-(3,6-dichloropyridazin-4-yl)carbamoyl]-4-hydroxycoumarin, 4-hydroxy-3-[N-(2-pyridinylcarbamoyl)courmarin, 4-hydroxy-3-[N(3-pyridinylcarbamoyl)courmarin, 7-trifluoromethyl-3-[N-(3-chloro-5-trifluoromethylpyridin-2-yl)carbamoyl]-4- hydroxycoumarin, 3-[N-(6-chloropyridin-3-yl)carbamoylJ-4-hydroxycoumarin, 3-[N-(6-methylpyridin-2-yl)carbamoyl]-4-hydroxycoumarin, 3-[N-(5-bromopyridin-2-yl)carbamoyl]-7-medιoxy-4-hydroxycoumarin, or 3-[N-(2,6-dichloropyridin-4-yl)carbamoyl]-4-hydroxycoumarin. 11. An anthelmintic composition for administration to animals comprising a physiologically acceptable carrier and adjuvants, and an effective anthelmintic amount of a 3-carbamoyl-4- hydroxycoumarin, hydrate thereof, or pharmaceutically acceptable salt thereof of the formula: wherein X is selected from the group consisting of (1) 4-halophenyl (A); (2) 4-R 4 phenyl (A') (3) (5-R' 5 H,3,4-thiadiazol-2-yl (B); (4) (2-SR" 5 )-l,3,4-thiadiazol-5-yl (C); (5) pyridin-2-yl (X) (6) pyridin-3-yl (Y) (7) pyridin- -yl (Z) (8) pyrimidin-5-yl (F); (9) pyrazin-2-yl (G); (10) pyrimidin-2-yl (H); (11) -NH-phenyl (I); (12) 4-[di(C 1 -C 5 )alkoxyphosphonomedιyl]phenyl (J); or (13 i 4-(pyridin^~ylmedιyl)phenyl (K); wherein the variable substituents (1) and (2) are optionally substituted at die 2 position of the phenyl moiety with halogen (Cl, Br, F. or I); wherein the variable substituents (5)-(l 1) are optionally substituted widi one. two or three members selected from the group consisting of halogen (Ci. Br, F or I), CN, CF 3 . C j ^ alkyl or CJ-C5 alkoxy; wherein the variable substituent (13) is optionally substituted in die pyridinyl moiety with one or two members selected from the group consisting of halogen (Cl. Br, F or I), CN, CF^, C C 5 alkyl or CJ-C5 alkoxy; wherein R is selected from the group consisting of hydrogen, phenyl, halogen (Cl, Br, F or I), CN, CF 3 , Ci-C ζ alkyl or C C 5 alkoxy, widi the proviso that when X is 4-halophenyl (A), R is Ci, F, Br, CF 3 or phenyl; wherein R 4 is selected from cyano (-C*N), trifluoromethyl, C C 4 alkyl, phenylhydroxymethyl (-CHOH-phenyl), hexafluoro-2-hydroxyisopropy! (-C(CF 3 ) 2 OH), or trifluoromethoxy (-O-CF 3 ). wherein R'5 is selected from a halogen (Cl, Br, F. or I) atom, cyano, -CF 3 , -CF 2 C1, -CF 2 CF 3 , benzyl, benzyl substituted widi [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C J -C5 alkyl or C j -C 5 alkoxy], pyridin-2- yl, pyridin-2-yl substituted widi [one. two or three members selected from die group consisting of halogen (Cl, Br, F or I), CN. CF 3 , C r C 5 alkyl or C r C 5 alkoxy], pyridin-3-yl, pyridin-3-yl substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br. F or I). CN, CF 3 , C1-C5 alkyl or C j -C 5 alkoxy], pyridin-4-yl, pyridin^4-yl substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C r C 5 alkyl or C^ alkoxy]; wherein R" 5 is selected from hydrogen, C1-C5 alkyl, halogen (Cl, Br, F, or I), cyano, - CF 3 , -CF 2 C1, -CF 2 CF 3 , phenyl, phenyl substituted widi [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C j -C5 alkyl or C1-C5 alkoxy], benzyl, benzyl substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C j -C^ alkyl or C^ alkoxy], pyridin-2-yl, pyridin-2-yl substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C j -Cs alkyl or C^ alkoxy], pyridin-3-yl, pyridin-3-yl substituted with [one, two or three members selected from die group consisting of halogen (Cl, Br, F or I), CN, CF 3 , Ci-Cs alkyl or C j -Cs alkoxy], pyridin-4-yl, pyridin-4-yl substituted widi [one, two or tiiree members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , 0^5 alkyl or C^Cs alkoxy]; pyridin-2-yKCH^-, pyridin^-y CH^ substituted widi [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I), CN, CF 3 , C1-C5 alkyl or C j -C 5 alkoxy], pyridin-3-yl(CH 2 )-, pyridin-3-yl(CH 2 )- substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I). CN, CF 3 , CJ-C5 alkyl or C j ^ alkoxy], pyridin-4-yl(CH2)-, pyridin^-y^CH^- substituted with [one, two or three members selected from the group consisting of halogen (Cl, Br, F or I). CN. CF 3 , C j -C 5 alkyl or C C5 alkoxy]; or hydrates or a pharmaceutically acceptable salt thereof; other than: 3-[N-(5-benzyl-l,3,4-thiadiazoI-2-yl)carbamoyl]-7-chloro-4-hydroxycoumarin, 7-chloro-4-hydroxy-3-[N-[5-(2-pyridinylmethyl)thio- l ,3,4-thiadiazol-5- yljcarbamoyljcoumarin, 7-chloro-4-hydroxy-3-[N-(5-phenyl-l,3,4-d iadiazol-2-ylJcarbamoyl]coumarin, 3-[N-(2-(benzylthio-l,3,4-tiιiadiazol-5-yl)carbamoyIJ-7-chloro-4-hydroxycoumarin, 3-[N-(3,6-dichloropyridazin-4-yl)carbamoyl]-4-hydroxycoumarin, 4-hydroxy-3-[N-(2-pyridinylcarbamoyl)courmarin, 4-hydroxy-3-[N(3-pyridinylcarbamoyl)courmarin, 7-trifluoromethyl-3-[N-(3-chloro-5-trifluoromethylpyridin-2-yl)carbamoyl]-4- hydroxycoumarin , 3-[N-(6-chloropyridin-3-yl)carbamoyl]-4-hydroxycoumarin, 3-[N-(6-methylpyridin-2-yl ' )carbamoyl]-4-hydroxycoumarin, 3-[N-(5-bromopyridin-2-yl)carbamoyl]-7-methoxy-4-hydroxycoumarin, or 3-[N-(2.6-dichloropyridin-4-yl)carbamoyl]-4-hydroxycoumarin. 12. A method of preventing or treating coccidiosis in fowl which comprises administering to fowl in need a tiierapeutic or prophylactic dosage of a 3-carbamoyl-4-hydroxycoumarin, hydrate thereof; or pharmaceutically acceptable salt thereof of the formula: IW wherein R' 2 is hydrogen, CF 3 or halogen (Cl, Br, F or I), R' 4 is Br, F, Cl or CF 3 and R * is Br, F or CF 3 ; other than 3-[N-(4-chlorophenyI)carbamoyl]-7-trifluoromethyl-4-hydroxycoumarin. 13. A compound according to Claim 1 wherein d e compound, hydrate or pharmaceutically acceptable acid addition salt tiiereof is 7-bromo-3-[N-[4-chlorophenyl)carbamoyl]-4- hydroxycou arin or 7-bromo-3-[N-[4-(2,4difluoro)phenyl)carbamoyl]-4-hydroxycoumarin.

Inventors: CLOTHIER MICHAEL F, LEE BYUNG HYUN, CLOTHIER, MICHAEL, F., LEE, BYUNG, HYUN
Applicants: UPJOHN CO, THE UPJOHN COMPANY
Application year: 1991
Main classification: C07D417
IPC codes: A61K31, A61P33, C07D311, C07D405, C07D417, C07F9